271 related articles for article (PubMed ID: 36452200)
1. Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.
Alsayejh B; Kietsiriroje N; Almutairi M; Simmons K; Pechlivani N; Ponnambalam S; Ajjan RA
TH Open; 2022 Oct; 6(4):e396-e407. PubMed ID: 36452200
[TBL] [Abstract][Full Text] [Related]
2. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
Sakata Y; Aoki N
J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
[TBL] [Abstract][Full Text] [Related]
3. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Bagoly Z; Baráth B; Orbán-Kálmándi R; Szegedi I; Bogáti R; Sarkady F; Csiba L; Katona É
Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33669007
[TBL] [Abstract][Full Text] [Related]
5. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
[TBL] [Abstract][Full Text] [Related]
6. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
7. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
Aoki N; Moroi M; Tachiya K
Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
[TBL] [Abstract][Full Text] [Related]
8. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
9. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
Gaule TG; Ajjan RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
[TBL] [Abstract][Full Text] [Related]
10. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
11. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
Sakai M; Watanuki M; Matsuo O
Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
[TBL] [Abstract][Full Text] [Related]
13. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
14. Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.
Sun M; Hao Pontius MH; Yang S; Pendekanti T; Raghunathan S; Shavit JA; Sen Gupta A
J Thromb Haemost; 2023 Apr; 21(4):983-994. PubMed ID: 36696210
[TBL] [Abstract][Full Text] [Related]
15. The hemostatic system.
Stassen JM; Arnout J; Deckmyn H
Curr Med Chem; 2004 Sep; 11(17):2245-60. PubMed ID: 15379710
[TBL] [Abstract][Full Text] [Related]
16. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom.
Cheng AC; Tsai IH
Biochim Biophys Acta; 2014 Jan; 1840(1):153-9. PubMed ID: 23999090
[TBL] [Abstract][Full Text] [Related]
18. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
[TBL] [Abstract][Full Text] [Related]
19. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties.
Bryk AH; Natorska J; Ząbczyk M; Zettl K; Wiśniewski JR; Undas A
J Proteomics; 2020 Oct; 229():103946. PubMed ID: 32810596
[TBL] [Abstract][Full Text] [Related]
20. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice.
Ząbczyk M; Ariëns RAS; Undas A
Cardiovasc Res; 2023 Mar; 119(1):94-111. PubMed ID: 36662542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
